PLX Protalix BioTherapeutics, Inc.

1.08
-0.08  -6.9%
Previous Close 1.16
Open 1.09
Price To book 0.00
Market Cap 107.81M
Shares 99,821,000
Volume 8,845,045
Short Ratio 0.78
Av. Daily Volume 3,136,470

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 dosing commenced October 2016. 1-year data due mid-2018.
PRX-102
Fabry disease
Phase 2 interim data released January 3, 2017. Full data due 1Q 2017.
AIR DNase (PRX-110)
Cystic Fibrosis
Phase 2 trial initiation announced November 30, 2016. Data due 2H 2017.
OPRX-106
Ulcerative Colitis